Long-term acetyl-L-carnitine treatment in Alzheimer's disease.

Spagnoli, A; Lucca, U; Menasce, G; Bandera, L; Cizza, G; Forloni, G; Tettamanti, M; Frattura, L; Tiraboschi, P; Comelli, M

Spagnoli, A; Lucca, U; Menasce, G; Bandera, L; Cizza, G; Forloni, G; Tettamanti, M; Frattura, L; Tiraboschi, P; Comelli, M.

Affiliation

Spagnoli A; Mario Negri Institute for Pharmacological Research, Milan, Italy.

Neurology ; 41(11): 1726-32, 1991 Nov.

Article in En | MEDLINE | ID: mdl-1944900

Subject(s)

Acetylcarnitine/therapeutic use; Alzheimer Disease/drug therapy; Acetylcarnitine/administration & dosage; Acetylcarnitine/adverse effects; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease/psychology; Analysis of Variance; Cognition/drug effects; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Prognosis; Time Factors

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Acetylcarnitine / Alzheimer Disease Type of study: Clinical_trials / Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Neurology Year: 1991 Type: Article Affiliation country: Italy

Search on Google

XML

PubMed Links